MedPath

A trial of tranexamic acid in older adults after a head injury.

Phase 1
Conditions
Mild traumatic brain injury.
MedDRA version: 20.1Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 100000004863
Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21]
Registration Number
EUCTR2020-003391-40-GB
Lead Sponsor
ondon School of Hygiene and Tropical Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
10000
Inclusion Criteria

•70 years or older (actual or estimated)
•History or evidence of head injury (e.g. laceration, bruise, swelling or pain in head or face)
•GCS = 13
•Has one or more of the following symptoms:
ohas or had any impaired consciousness (loss of consciousness, amnesia, or confusion)
onausea or vomiting
•Within 3 hours of injury (do not include if y interval cannot be estimated e.g. patient unable to confirm time of fall or patient found on floor after an unwitnessed fall and home alone)
•Patient will be conveyed or is admitted to a participating hospital

Exclusion:
•Living in a nursing home, mental health institution or prison
•TXA is clearly indicated (e.g. major bleeding) or contraindicated (e.g. suspected stroke)
•Known to have a diagnosis of dementia
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range 0
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10000

Exclusion Criteria

•Living in a nursing home, mental health institution or prison
•TXA is clearly indicated (e.g. major bleeding) or contraindicated (e.g. suspected stroke)
•Known to have a diagnosis of dementia

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath